CTRI/2009/091/000481未知3 期
FEASIBILITY STUDY OF THE SAFETY AND ACTIVITY OF AUTOLOGOUS BONE MARROW ASPIRATE CONCENTRATE (BMAC) FOR THE TREATMENT OF NON RECONSTRUCTABLE CRITICAL LIMB ISCHEMIA DUE TOPERIPHERAL ARTERIAL OCCLUSIVE DISEASE
Harvest Technologies, Boston USA1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 待定
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Time points: 6 months; visual analogue pain scale, Quality of life questionaire
研究概览
简要总结
The purpose of this feasibility study is to provide clinical data demonstrating the safety and activity of a concentrate of nucleated cells from bone marrow aspirate (BMAC) produced with the Harvest Bone Marrow Aspirate Concentrate System for treating lower limbs of patients diagnosed with critical limb ischemia (CLI) due to peripheral arterial occlusive disease (PAOD). The study will evaluate the hypothesis that BMAC prepared from bone marrow aspirate, when injected intramuscularly and/or intraarterial in areas of ischemia in the lower extremity, has the potential to improve perfusion within the ischemic limb and reduce limb amputation. Sixy (60) study subjects will be enrolled in a prospective, two arm, open label, single center study
研究设计
- 分配方式
- Other
- 盲法
- Open Label
入排标准
入选标准
- •Subjects must meet all of the following inclusion criteria to be enrolled in the trial 1.Diagnosis of Critical Limb Ischemia per protocol (see diagnostic criteria #2) with regard to the study limb.Existence of a PAOD with clinical presentation corresponding to Rutherford Category 4 or Category 5 as defined in the reporting standards adopted by the Society of Vascular Surgeons (table 1)2.Patient meets at least one of the following diagnostic criteria in the study limb:a.Ankle artery occlusion pressure absolute <50 mmHg or ABI <0.4 b.Toe artery occlusive pressure < 40mm Hg or TBI (<0.4)c.TcPO2 <20 mmHg lying down breathing room air, if available.3.There is no reasonable open surgical or endovascular revascularization option as determined by the treating vascular specialist.
- •Factors that may contribute to the determination of inoperability may include: a.
- •Anatomical considerations
- •No outflow targets
- •No appropriate conduit (i.e. vein for bypass)
- •Long segment occlusions or calcified lesions that predict poor outcome with endovascular approaches.
- •High risk medical conditions
- •Unstable cardiac disease.
- •Renal insufficiencyc.History of prior failed revascularization attemptsd.The patient?s unsuitability must be confirmed by 2 qualified physicians.
- •The attending vascular surgeon will provide the primary assessment.
- •The confirmatory opinion must come from a fully licensed physician.
- •(not a resident)
- •If anatomical considerations are invoked, the second physician may be a vascular surgeon, interventional radiologist, cardiologist, or vascular medicine specialist.
- •If medical co-morbidity is deemed the high risk aspect, then the confirmatory opinion may be obtained from an internist, family physician, cardiologist, vascular medicine, nephrologists, or vascular surgeon.4.Age >18 years and ability to understand the planned treatment5.Subject has read and signed the IRB/IEC approved Informed Consent form 6.Patients for whom the following medication(s) is prescribed must have a one month stable baseline of appropriate/maximally tolerated therapy prior to enrollment: Plavix/asprin therapy, anticoagulation therapy, cholesterol lowering agent, and or blood pressure medication 7.Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, INR ≤ 1.6 unless on Coumadin, or PTT <1.5 x control (to avoid bleeding complications) Patients on Coumadin will be corrected prior to the procedure and must have an INR<1.6 at the time of randomization/surgery.
排除标准
- •Subjects will be excluded if they meet any of the exclusion criteria:1.Life expectancy <6 months due to concomitant illnesses2.History of bone marrow diseases (especially NHL, MDS) that prohibit transplantation3.Terminal renal failure with existing dependence on dialysis4.Known active malignancy or results outside of normal limits from the following tests: PAP, Chest X-ray, PSA, Mammogram, Hemocult unless follow-up studies reveal patient to be cancer free..5Poorly controlled diabetes mellitus (HgbA1C>10%)6Medical risk that precludes anesthesia (conscious sedation), or ASA Class 57.Life-threatening complications of the ischemia necessitating immediate amputation8.Uncorrected iliac artery occlusion on index side 9.Extensive necrosis of the index limb or other conditions that make amputation inevitable (Rutherford Category 6)10.Active clinical infection being treated by antibiotics within one week of enrollment11.Treatment with immunosuppressant drugs (including Prednisone > 5 mg per day).12.Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method.13.Underwent a major cardiovascular surgical procedure (carotid endarterectomy, open arterial aneurysm or bypass surgery, or coronary artery bypass surgery) or an adverse cardiovascular event (stroke or MI) within the 30 days prior to randomization.
结局指标
主要结局
Time points: 6 months; visual analogue pain scale, Quality of life questionaire
时间窗: The following three clinical outcomes will be recorded:Subject?s perception of pain (analog pain scale).Amputation-free survivalPain-free walking distance (claudication)
次要结局
- Laboratory and Quality of Life EndpointsChange in TcPO2Change in ABI, TBIChange in quality of life (based on Rand-36 questionnaires).Reduction in pain medication(The following three clinical outcomes will be recorded:Subject?s perception of pain (analog pain scale).Amputation-free survivalPain-free walking distance (claudication))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Feasibility Study of the Magnetic Anal Sphincter (FENIX System)Fecal IncontinenceNCT01625221Torax Medical Incorporated35
招募中
不适用
MR-Guided Focused Ultrasound in the Treatment of Focal Epilepsy (EP001)EpilepsyNCT02804230InSightec20
已完成
不适用
Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Acquired Brain Injury in a Clinical SettingNCT07050875ABLE Human Motion S.L.14
招募中
不适用
Feasibility study to evaluate the safety and effectiveness of radiofrequency ablation of the palidothalamic tract for the treatment of Parkinson's diseases diseaseParkinson's diseaseJPRN-UMIN000031138Tokyo Women's Medical University20
已完成
不适用
A Feasibility Study to Evaluate the Safety and Effectiveness of Implantation of Flowise Cerebral Flow Diverter (Flowise)Intracranial AneurysmNCT02609867Yonsei University10